IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks. Cambrex specializes in seamless technology transfers and quick onboarding to keep your program on track.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Cambrex offers cutting-edge capabilities in peptide development and manufacturing, combining innovative technologies, diverse applications and specialized expertise to meet the growing demand for peptide-based therapeutics.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
Cambrex’s executive team are seasoned life science professionals with extensive experience leading successful organizations. They provide the vision and strategy that has guided the company through 40 years of transformation — overseeing significant investments in capacity and new capabilities that will further solidify the company’s position as a leading CDMO. Most importantly, they lead by example demonstrating the importance of collaboration and customer service as a clear competitive advantage. Alongside a growing team of more than 2,000 employees, Cambrex leaders partner with customers in their quest to bring novel, life-changing therapies to the market.
Chief Executive Officer
Mr. Russolo joined Cambrex in 2002 and currently serves as Chief Executive Officer. During his tenure, he has held a series of leadership positions across the organization, including Chief Operating Officer, President of the Generic Drug Substance Business Unit, Vice President of Sales & Marketing, Marketing & Sales Director, and Area Manager for Cambrex Profarmaco Milano. Before joining Cambrex directly, he held roles at Cambrex-owned Conti B.P.C. and Seal Sands Chemicals.
Executive Vice President & Chief Financial Officer
Mr. Majewski joined Cambrex in September 2026 and currently serves as Executive Vice President and Chief Financial Officer. He previously worked for nine years with SK Capital Partners (a NY-based private equity firm) in a variety of senior financial and operational leadership roles at their portfolio companies Noramco, Extractas Bioscience, Purisys, Halo Pharmaceutical and Woodstock Sterile Solutions. Prior to that, he served as Executive Vice President of Nippon Steel’s US-based Standard Steel subsidiary. He spent his first five years with PricewaterhouseCoopers in their Pittsburgh audit practice.
Senior Vice President, Chief Legal and People Officer
Ms. Hanley joined Cambrex in April 2009 and currently serves as Senior Vice President, General Counsel and Corporate Secretary. She previously held the positions of Assistant General Counsel and Assistant Corporate Secretary from January 2013 until February 2015, and Senior Intellectual Property/Corporate Counsel and Assistant Secretary prior to that. Before joining Cambrex, Ms. Hanley worked at Alpharma Pharmaceuticals as Director of Intellectual Property and was an Associate with Lerner, David, Littenberg, Krumholtz & Mentlik, LLP, an intellectual property law firm.
Chief Scientific Officer & President, Snapdragon Chemistry
Dr. Bio joined Cambrex in 2023 and currently serves as Chief Scientific Officer, Cambrex and President, Snapdragon Chemistry (a Cambrex Company). Prior to serving as President & CEO of Snapdragon, Dr. Bio held roles at Amgen Inc. and Merck Research Laboratories. He is a member of the American Chemical Society and the American Association for the Advancement of Science and has published extensively on the topic of process development. He holds multiple patents and is a reviewer for several scientific journals.
Chief Business Officer
Mr. Fincher joined Cambrex in April 2017 and currently serves as Chief Business Officer. Mr. Fincher has served in various leadership roles at Cambrex, following roles in pharmaceuticals and contract services organizations across multiple disciplines including finance, marketing, strategy, and operations. Prior to that, Mr. Fincher held various positions in engineering, supply chain, and finance at Novartis.